Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Although the neurofibromatoses consist of at least three autosomal dominantly inherited disorders, neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis, NF1 represents a multisystem pleiotropic condition very different from the other two. NF1 is a genetic syndrome first manifesting in childhood; affecting multiple organs, childhood development, and neurocognitive status; and presenting the clinician with often complex management decisions that require a multidisciplinary approach. Molecular genetic testing (see article for detailed discussion) is recommended to confirm NF1, particularly in children fulfilling only pigmentary features of the diagnostic criteria. Although cancer risk is not the major issue facing an individual with NF1 during childhood, the condition causes significantly increased malignancy risks compared with the general population. Specifically, NF1 is associated with highly elevated risks of juvenile myelomonocytic leukemia, rhabdomyosarcoma, and malignant peripheral nerve sheath tumor as well as substantial risks of noninvasive pilocytic astrocytoma, particularly optic pathway glioma (OPG), which represent a major management issue. Until 8 years of age, clinical assessment for OPG is advised every 6 to 12 months, but routine MRI assessment is not currently advised in asymptomatic individuals with NF1 and no signs of clinical visual pathway disturbance. Routine surveillance for other malignancies is not recommended, but clinicians and parents should be aware of the small risks (<1%) of certain specific individual malignancies (e.g., rhabdomyosarcoma). Tumors do contribute to both morbidity and mortality, especially later in life. A single whole-body MRI should be considered at transition to adulthood to assist in determining approaches to long-term follow-up. Clin Cancer Res; 23(12); e46–e53. ©2017 AACR. See all articles in the online-only CCR Pediatric Oncology Series.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B., et al. (1993) · Nature · doi:10.1038/363515a0 · Cited by 1,420
Trofatter, J. (1993) · Cell · doi:10.1016/0092-8674(93)90406-g · Cited by 1,403
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Self-citationDeletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
Viskochil, D., Buchberg, A. M., Xu, G., Cawthon, R. M., Stevens, J., Wolff, R. K., Culver, M., Carey, J. C., Copeland, N. G., Jenkins, N. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90252-a · Cited by 1,082 · cited 1×
“The gene and disease-associated mutations for NF1 were identified in 1990 (6) and for NF2 in 1993 (7–9).”
BackgroundGuidelines for the diagnosis and management of individuals with neurofibromatosis 1
Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045906 · Cited by 1,053
Self-citationEvans, D. G., Howard, E., Giblin, C., Clancy, T., Spencer, H., Huson, S. M., & Lalloo, F. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33139 · Cited by 988
Self-citationVON RECKLINGHAUSEN NEUROFIBROMATOSIS: A CLINICAL AND POPULATION STUDY IN SOUTH-EAST WALES
HUSON, S. M., HARPER, P. S., & COMPSTON, D. A. S. (1988) · Brain · doi:10.1093/brain/111.6.1355 · Cited by 686 · cited 2×
“Series Huson (15) McGaughran (16) Update for key tumors”
BackgroundActivity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Dombi, E., Baldwin, A., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L. E., Rizvi, T. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605943 · Cited by 682
A Clinical, Pathological, and Genetic Study of Multiple Neurofibromatosis
(1956) · Journal of the American Medical Association · doi:10.1001/jama.1956.02970230087029 · Cited by 522 · cited 2×
“The clinical and genetic distinction between NF1 and NF2 was not fully recognized until the past three decades, and in prior reports, NF1 and NF2 were frequently referred to interchangeably (2).”
Background
Cited by
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Abdominal neoplastic manifestations of neurofibromatosis type 1
Dare, A. J., Gupta, A. A., Thipphavong, S., Miettinen, M., & Gladdy, R. A. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa032 · Cited by 27
Metadata
- Authors
- Evans, D. G. R., Salvador, H., Chang, V. Y., Erez, A., Voss, S. D., Schneider, K. W., Scott, H. S., Plon, S. E., & Tabori, U.
- Venue
- Clinical Cancer Research
- Published
- 2017-06-14
- Volume
- 23
- Issue
- 12
- Pages
- e46-e53
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2625944954
- Cited by
- 178
- References
- 48
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0589
- The paper
- Evans, D. G. R., Salvador, H., Chang, V. Y., Erez, A., Voss, S. D., Schneider, K. W., Scott, H. S., Plon, S. E., & Tabori, U. (2017). Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.